Perioperative Chemoimmunotherapy for Resectable Gastric and Gastroesophageal Junction Cancer: A Conceptual, Biomarker-Informed, and Regionally Adapted Framework. (PubMed, J Gastrointest Cancer) - Sep 30, 2026 - "MATTERHORN demonstrated significant event-free survival and subsequently overall survival benefits with perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT), supporting regulatory approvals. In contrast, KEYNOTE-585 increased pathological complete response but did not meet the prespecified event-free survival statistical boundary, while ATTRACTION-5 did not establish postoperative nivolumab after D2 gastrectomy as a new standard...Perioperative treatment should integrate resectability, surgical quality, patient fitness, regional chemotherapy backbones, MSI-H/dMMR status, treatment completion, and postoperative recovery. The proposed framework is conceptual rather than a guideline and requires prospective validation."
Biomarker • IO biomarker • Journal • Review • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Microsatellite Instability • Oncology • Solid Tumor • MSI • PD-L1
|
|
Hiroyuki Nagashima; Koshi Fujikawa; Tamotsu Sagawa
|